News and advice from an investor-CEO, with Milenko Cicmil

pharmaphorum caught up with Milenko Cicmil to talk about Tasca Therapeutics’ news at LSX: their first patient dosed for lead asset CP-383.

From prostate cancer to breast cancer: In conversation with ...

Exploring the unconventional to provide hope: Dr Jason Willi...

Following science to fruition, putting patients first: An AS...

At ASCO25, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial. Alison Dziarmaga discussed the data with pharmaphorum.

Taking chemotherapy directly to skin lesions, with Dr Raza B...

At BIO 2025 in Boston, editor-in-chief Jonah Comstock spoke with Dr Raza Bokhari, CEO of Medicus Pharma.

Johnson & Johnson, ASCO 2025: Redefining global cancer care

Mark Wildgust, VP of global medical affairs, oncology, at Johnson & Johnson Innovative Medicine, discusses J&J’s ambition to get in front of cancer.